ArticleJCI insight2022
A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy.
Devivasha Bordoloi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papercites it